Therapeutic solutions for neurodegeneration


There is currently no available treatment to slow down or stop diseases related to neurodegeneration. They affect tens of millions of persons worldwide.

Alzprotect designs and develops innovative therapeutic solutions for these diseases.

An exceptional therapeutic potential for the treatment of tauopathies – Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease.

Schematic diagram of the action of AZP2006

Novel mechanism of action and promising therapeutic effects, acting on all known markers of neurodegeneration:
Amyloid beta peptide, Tau protein, Neuroinflammation, Oxidative stress.

Learn more about
AZP2006 molecule

News

Positive feedback from the EMA and FDA on Alzprotect's Phase 2b/3 development strategy for PSP

Loos March 13Th 2024

ALZPROTECT is thrilled to announce that it has received favorable feedback from both the American (FDA) and European (EMA) authorities regarding the regulatory path for advancing the clinical development of Ezeprogind/AZP2006 for patients with PSP. This significant milestone follows the already very promising results of the phase 2a study in PSP and marks a decisive advancement. It will provide a clear path for the further development of Ezeprogind/AZP2006 within both sc...

ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT

Loos, september 21st 2023

World Alzheimer’s day 2023

ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT

Alzprotect, a biopharmaceutical company based in Lille, is currently testing an innovative drug against a neurodegenerative disease closely related to Alzheimer's disease. The very good results obtained have allowed Alzprotect to extend the clinical trial of this treatment for 6 months, and to prepare a larger scale study. The m...

 

All news